All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Pirtobrutinib Demonstrates ORR Noninferiority vs Ibrutinib in BTK Inhibitor–Naive CLL/SLL

July 29th 2025

In BRUIN CLL-314, pirtobrutinib met the primary end point of noninferior ORR vs ibrutinib in both the ITT and pretreated subsets of patients with CLL/SLL.

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL

July 29th 2025

A supplemental new drug application for all-oral, fixed-duration acalabrutinib plus venetoclax in treatment-naive CLL has been submitted to the FDA.

Novel LYN/BTK Dual Inhibitor Yields Durable Responses in Heavily Pretreated CLL/SLL

July 29th 2025

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

IHC Testing Could Serve as Surrogate to NGS for Early Detection of TP53-Mutant MDS/AML

July 29th 2025

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

IMpact-MF Trial Aims to Show OS Benefit of Imetelstat in Relapsed Myelofibrosis

July 29th 2025

John Mascarenhas, MD, discusses the rationale for evaluating imetelstat in patients with relapsed/refractory myelofibrosis.

Knowledge of Unique ADC-Related Toxicities Is Critical for Safe, Effective Use in NSCLC

July 28th 2025

Corey J. Langer, MD, FACP, provides a focused overview of antibody-drug conjugate–related toxicities and AE management in lung cancer.

Efforts to Yield Greater OS Benefit With EGFR TKIs Continue in Early-Stage EGFR+ NSCLC

July 28th 2025

Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.

How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive

July 28th 2025

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

$31 Million Pledged to Establish the Sigma Chi Center for Advanced Therapeutics and Innovation

July 28th 2025

Huntsman Cancer Foundation and Sigma Chi International Fraternity announced a $31 million pledge for the Sigma Chi Center for Advanced Therapeutics.

Vimseltinib Earns Positive CHMP Recommendation for TGCT

July 28th 2025

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

FDA Grants Priority Review to Perioperative Durvalumab in Resectable Gastric/GEJ Cancer

July 28th 2025

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

Perioperative Tislelizumab Receives Positive CHMP Opinion for High-Risk Resectable NSCLC

July 28th 2025

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

IHC Testing May Bridge Gaps With NGS for Early Identification, Intervention in TP53-Mutant MDS and AML

July 28th 2025

Shyam A. Patel, MD, PhD, and Jonathan M. Gerber, MD, discuss the next steps for validating IHC as a biomarker for TP53 mutations in MDS and AML.

Lineage Plasticity and Treatment Resistance Highlight Need for Personalized mCRPC Strategies

July 28th 2025

Jue Wang, MD, outlines how prolonged androgen suppression may drive prostate cancer evolution.

Immunotherapy Sequencing Must Be Personalized During Therapy Selection for Metastatic RCC

July 28th 2025

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

Array of Agents Allow for Treatment Individualization in ROS1+ NSCLC

July 27th 2025

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 7/20

July 27th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC

July 26th 2025

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 7/20

July 26th 2025

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC

July 26th 2025

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.